Oscar Health (OSCR) Expected to Announce Earnings on Tuesday

Oscar Health (NYSE:OSCR) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $3.1234 billion for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.

Oscar Health (NYSE:OSCR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. Oscar Health had a negative return on equity of 21.50% and a negative net margin of 2.16%.The business had revenue of $2.93 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The firm’s revenue was up 23.2% on a year-over-year basis. On average, analysts expect Oscar Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Oscar Health Price Performance

Shares of OSCR opened at $12.24 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.67. Oscar Health has a 1 year low of $11.20 and a 1 year high of $23.80. The stock has a market cap of $3.24 billion, a P/E ratio of -10.93 and a beta of 1.90. The stock’s 50-day moving average price is $15.60 and its two-hundred day moving average price is $16.76.

Insider Activity at Oscar Health

In other news, insider Adam Mcananey sold 1,852 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $16.59, for a total value of $30,724.68. Following the sale, the insider directly owned 179,241 shares in the company, valued at $2,973,608.19. The trade was a 1.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mario Schlosser sold 23,038 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.65, for a total value of $406,620.70. Following the transaction, the insider owned 350,180 shares of the company’s stock, valued at approximately $6,180,677. The trade was a 6.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 483,307 shares of company stock valued at $7,635,300. 24.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Oscar Health

Several institutional investors have recently bought and sold shares of OSCR. Thrive Capital Management LLC grew its stake in shares of Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after acquiring an additional 1,588,395 shares in the last quarter. Baird Financial Group Inc. acquired a new position in Oscar Health during the first quarter worth $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Oscar Health by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company’s stock valued at $2,827,000 after purchasing an additional 8,879 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after buying an additional 2,242 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Oscar Health by 39.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company’s stock valued at $6,169,000 after buying an additional 132,149 shares during the last quarter. Institutional investors own 75.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on OSCR shares. Piper Sandler upgraded shares of Oscar Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $13.00 to $25.00 in a research report on Tuesday, November 25th. The Goldman Sachs Group initiated coverage on shares of Oscar Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $17.00 target price on the stock. UBS Group raised shares of Oscar Health from a “sell” rating to a “neutral” rating and boosted their price target for the company from $12.00 to $17.00 in a report on Friday, January 9th. Wall Street Zen cut shares of Oscar Health from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Wells Fargo & Company reduced their target price on Oscar Health from $14.00 to $11.00 and set an “underweight” rating on the stock in a report on Thursday, November 13th. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $17.00.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.